Skip to main content

Recombinant Viral 136R/Y136 Protein

R&D Systems, part of Bio-Techne | Catalog # 8976-BR

Type I and III Interferon Inhibitor
R&D Systems, part of Bio-Techne
Catalog #
Availability
Size / Price
Qty
Loading...
Carrier Free
8976-BR-025/CF

Catalog #
Availability
Size / Price
Qty
With Carrier
8976-BR-025

Key Product Details

Source

CHO

Conjugate

Unconjugated

Applications

Bioactivity

Product Specifications

Source

Chinese Hamster Ovary cell line, CHO-derived viral 136R protein
Viral 136R/Y136
(Tyr17-Lys351)
Accession # Q9DHH7
HPGGGSGGGSGGGS HHHHHH
N-terminus C-terminus

Purity

>95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.

Endotoxin Level

<0.10 EU per 1 μg of the protein by the LAL method.

N-terminal Sequence Analysis

Tyr17

Predicted Molecular Mass

41 kDa

SDS-PAGE

88-120 kDa, reducing conditions

Activity

Measured by its ability to inhibit Type-I and Type-III IFN-mediated anti-viral activity. Huang, J. et al. (2007) PANS 104:9822.
The ED50 for this effect is 2-12 ng/mL in the presence of 20 pg/mL Recombinant Human IFN-beta (Catalog # 8499-IF).

Formulation, Preparation and Storage

Carrier Free
What does CF mean?

CF stands for Carrier Free (CF). We typically add Bovine Serum Albumin (BSA) as a carrier protein to our recombinant proteins. Adding a carrier protein enhances protein stability, increases shelf-life, and allows the recombinant protein to be stored at a more dilute concentration. The carrier free version does not contain BSA.

What formulation is right for me?

In general, we advise purchasing the recombinant protein with BSA for use in cell or tissue culture, or as an ELISA standard. In contrast, the carrier free protein is recommended for applications, in which the presence of BSA could interfere.

Carrier: 8976-BR
Formulation Lyophilized from a 0.2 μm filtered solution in PBS with BSA as a carrier protein.
Reconstitution Reconstitute at 500 μg/mL in PBS.
Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.
Carrier Free: 8976-BR/CF
Formulation Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose.
Reconstitution Reconstitute at 500 μg/mL in PBS.
Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.

Background: 136R

136R, also known as Y136, is an approximately 80 kDa glycosylated and secreted protein encoded by the Yaba-like disease virus genome (1). 136R binds directly to type I and type III interferons (IFN-alpha and IFN-lambda) (1). It prevents the interaction of rhesus and human IFN-alpha as well as human IFN-beta with the IFN-gamma R1 complex, although it shares only 14% amino acid sequence identity with the ECD of human IFN-gamma R1 (1). 136R blocks STAT1 signaling and the anti-viral protective functions of IFN-alpha, -beta, -omega, -kappa, and -lambda 1/IL-29 (1).

References

  1. Huang, J. et al. (2007) Proc. Natl. Acad. Sci. USA 104:9822.

Long Name

Soluble Type I Interferon Receptor 136R

Additional 136R Products

Product Documents for Recombinant Viral 136R/Y136 Protein

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Note: Certificate of Analysis not available for kit components.

Product Specific Notices for Recombinant Viral 136R/Y136 Protein

For research use only

Loading...
Loading...
Loading...
Loading...